Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis

Amanda Psyrri, Ziwei Yu, Aris Bamias, Paul Maurice Weinberger, Sonia Markakis, Diane Kowalski, Robert L. Camp, David L. Rimm, Meletios A. Dimopoulos

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The cellular inhibitor of apoptosis protein (cIAP) is regarded as an important prognostic biomarker in cancer. Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers, treated with surgical debulking followed by platinum/paclitaxel-based combination chemotherapy, was constructed. For evaluation of protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis. Results: The mean follow-up time for the entire cohort was 34.4 months. Patients with tumors bearing high cIAP membranous expression had a 3-year survival rate of 31% compared with 73% for patients with low cIAP expressing tumors (P = 0.0020). In multivariable analysis, adjusting for well-characterized prognostic variables, low membranous cIAP expression level was the only significant prognostic factor for overall survival. Conclusions: Our results indicate that cIAP protein levels have prognostic value in ovarian cancer patients. Modulation of cIAP levels may improve clinical outcome in ovarian cancer.

Original languageEnglish (US)
Pages (from-to)1179-1183
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number6
DOIs
StatePublished - Jun 1 2006

Fingerprint

Inhibitor of Apoptosis Proteins
Proteins
Ovarian Neoplasms
Tumor Biomarkers
Paclitaxel
Ovarian epithelial cancer
Combination Drug Therapy
Platinum
Fluorescent Antibody Technique
Neoplasms
Survival Rate
Survival

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. / Psyrri, Amanda; Yu, Ziwei; Bamias, Aris; Weinberger, Paul Maurice; Markakis, Sonia; Kowalski, Diane; Camp, Robert L.; Rimm, David L.; Dimopoulos, Meletios A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 6, 01.06.2006, p. 1179-1183.

Research output: Contribution to journalArticle

Psyrri, Amanda ; Yu, Ziwei ; Bamias, Aris ; Weinberger, Paul Maurice ; Markakis, Sonia ; Kowalski, Diane ; Camp, Robert L. ; Rimm, David L. ; Dimopoulos, Meletios A. / Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 6. pp. 1179-1183.
@article{dc59dd14f8754e68b69fe40847cb63f8,
title = "Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis",
abstract = "Purpose: The cellular inhibitor of apoptosis protein (cIAP) is regarded as an important prognostic biomarker in cancer. Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers, treated with surgical debulking followed by platinum/paclitaxel-based combination chemotherapy, was constructed. For evaluation of protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis. Results: The mean follow-up time for the entire cohort was 34.4 months. Patients with tumors bearing high cIAP membranous expression had a 3-year survival rate of 31{\%} compared with 73{\%} for patients with low cIAP expressing tumors (P = 0.0020). In multivariable analysis, adjusting for well-characterized prognostic variables, low membranous cIAP expression level was the only significant prognostic factor for overall survival. Conclusions: Our results indicate that cIAP protein levels have prognostic value in ovarian cancer patients. Modulation of cIAP levels may improve clinical outcome in ovarian cancer.",
author = "Amanda Psyrri and Ziwei Yu and Aris Bamias and Weinberger, {Paul Maurice} and Sonia Markakis and Diane Kowalski and Camp, {Robert L.} and Rimm, {David L.} and Dimopoulos, {Meletios A.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1158/1055-9965.EPI-06-0120",
language = "English (US)",
volume = "15",
pages = "1179--1183",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis

AU - Psyrri, Amanda

AU - Yu, Ziwei

AU - Bamias, Aris

AU - Weinberger, Paul Maurice

AU - Markakis, Sonia

AU - Kowalski, Diane

AU - Camp, Robert L.

AU - Rimm, David L.

AU - Dimopoulos, Meletios A.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Purpose: The cellular inhibitor of apoptosis protein (cIAP) is regarded as an important prognostic biomarker in cancer. Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers, treated with surgical debulking followed by platinum/paclitaxel-based combination chemotherapy, was constructed. For evaluation of protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis. Results: The mean follow-up time for the entire cohort was 34.4 months. Patients with tumors bearing high cIAP membranous expression had a 3-year survival rate of 31% compared with 73% for patients with low cIAP expressing tumors (P = 0.0020). In multivariable analysis, adjusting for well-characterized prognostic variables, low membranous cIAP expression level was the only significant prognostic factor for overall survival. Conclusions: Our results indicate that cIAP protein levels have prognostic value in ovarian cancer patients. Modulation of cIAP levels may improve clinical outcome in ovarian cancer.

AB - Purpose: The cellular inhibitor of apoptosis protein (cIAP) is regarded as an important prognostic biomarker in cancer. Here, we sought to determine the prognostic value of cIAP protein levels in epithelial ovarian cancer using a novel method of compartmentalized in situ protein analysis. Methods: A tissue array composed of 150 advanced-stage ovarian cancers, treated with surgical debulking followed by platinum/paclitaxel-based combination chemotherapy, was constructed. For evaluation of protein expression, we used an immunofluorescence-based method of automated in situ quantitative measurement of protein analysis. Results: The mean follow-up time for the entire cohort was 34.4 months. Patients with tumors bearing high cIAP membranous expression had a 3-year survival rate of 31% compared with 73% for patients with low cIAP expressing tumors (P = 0.0020). In multivariable analysis, adjusting for well-characterized prognostic variables, low membranous cIAP expression level was the only significant prognostic factor for overall survival. Conclusions: Our results indicate that cIAP protein levels have prognostic value in ovarian cancer patients. Modulation of cIAP levels may improve clinical outcome in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=33745698082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745698082&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0120

DO - 10.1158/1055-9965.EPI-06-0120

M3 - Article

VL - 15

SP - 1179

EP - 1183

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 6

ER -